ArticleScientific reports2022
Results of the gErman migraine PatIent Survey on medical Care and prOPhylactic treatment Experience (EPISCOPE).
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Evolution of use and overuse of triptans in Austria - What has changed in the last 15 years?The journal of headache and pain · 2026Article
- Use of Non-Pharmacological Approaches for Migraine Treatment: Results from the Migraine in Aotearoa New Zealand Survey.Journal of clinical medicine · 2025Article
- Overview of migraine care, impact of the disease, and patient experience in France through patient voices: a cross-sectional and participatory survey study.The journal of headache and pain · 2025Article
- The epidemiology and unmet need of migraine in five european countries: results from the national health and wellness survey.BMC public health · 2025Article
- Consistency between headache diagnoses and ICHD-3 criteria across different levels of care.The journal of headache and pain · 2025Article
- Characterizing barriers to care in migraine: multicountry results from the Chronic Migraine Epidemiology and Outcomes - International (CaMEO-I) study.The journal of headache and pain · 2024Article
- Consumer Likelihood to Seek Information on OTC Medicines.Pharmacy (Basel, Switzerland) · 2023Article
- Consumer Impressions of the Safety and Effectiveness of OTC Medicines.Pharmacy (Basel, Switzerland) · 2023Article
- The relationship between headache-attributed disability and lost productivity: 3 Attack frequency is the dominating variable.The journal of headache and pain · 2023Article
- The Hidden Economic Consequences of Migraine to the UK Government: Burden-of-Disease Analysis Using a Fiscal Framework.Journal of health economics and outcomes research · 2023Article
- Minor Ailments in Older Adults: A Study of Prevalence and Health-Related Behaviors.Journal of primary care & community healthArticle
- Evolving care pathways for women with migraine in Italy: results from a national survey.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Migraine affects about 12% of the worldwide population causing substantial personal and societal burden. Yet, migraine remains underdiagnosed and untreated. EPISCOPE was a web-based survey among a German migraine patient cohort to characterize the medical care and prophylactic treatment status aiming to identify unmet needs. Potential migraine patients were identified via an ID Migraine screener. Their socioeconomic background, medical care experience, acute medication use, as well as use and experience of migraine prophylaxis was assessed by a questionnaire. Data of 29,011 participants was collected. 21,504 participants were identified as migraine patients. Patients with a higher number of monthly migraine days experienced better medical care. However, even among chronic migraine patients, 54% were not consulting a physician, 30% did not feel well-informed about medication overuse and 48% had never tried prophylactic migraine treatment. Among patients receiving prophylactic migraine treatment, up to 33% were not satisfied with their prophylaxis due to insufficient efficacy. Taken together, EPISCOPE describes the largest German migraine patient cohort so far. The survey provides detailed and valuable insight into the current medical care and prophylactic treatment situation in a highly developed European country and identifies reasons why the medical care of migraine patients is still insufficient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.